SCHEMBL25008034

SCHEMBL25008034

CC(C)(c1cccc(Cl)c1)C(O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 1/20 0.41
AOC3 Q16853 1/20 0.41
KIF11 P52732 4/20 0.40
LMNA P02545 1/20 0.39
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39
SLC6A2 P23975 3/20 0.38
SLC6A4 P31645 3/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KCNH2 Q12809 1/20 0.38
CYP19A1 P11511 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
VNN1 O95497 1/20 0.36
CNR1 P21554 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25517661 0.92 ACP3 (0.39) ACP3AOC3ADRB2ADRB1ADRB3
SCHEMBL25517986 0.90 CYP19A1 (0.41) KIF11SLC6A2SLC6A4ALDH1A1SLC6A3
SCHEMBL25517790 0.86 MEN1 (0.37) SLC6A2SLC6A4ALDH1A1SLC6A3CYP19A1
SCHEMBL25517749 0.86 ACP3 (0.36) ACP3KIF11ALDH1A1CYP19A1MEN1
SCHEMBL25517648 0.84 OPRM1 (0.39) SLC6A2SLC6A4CYP19A1MEN1KMT2A
SCHEMBL30174586 0.83 UGT2B7 (0.46) AOC3SLC6A2SLC6A4CYP3A4CYP2D6
SCHEMBL25517721 0.83 UGT2B7 (0.46) AOC3SLC6A2SLC6A4CYP3A4CYP2D6
SCHEMBL6666755 0.82 AOC3 (0.52) AOC3LMNASLC6A2SLC6A4ALDH1A1
SCHEMBL30174887 0.81 ADRB2 (0.42) AOC3KIF11ADRB2ADRB1ALDH1A1
SCHEMBL25518165 0.81 ADRB2 (0.42) AOC3KIF11ADRB2ADRB1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240398757-A1 INHIBITORS FOR CORONAVIRUSES COCRYSTAL PHARMA, INC. 2024-12-05 US disclosed
EP-4380920-A1 INHIBITORS FOR CORONAVIRUSES Cocrystal Pharma, Inc. (US) 2024-06-12 EP disclosed
CN-118103351-A Coronavirus inhibitors 共晶制药公司 2024-05-28 CN disclosed
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-25 US disclosed
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-25 US disclosed
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-25 US disclosed
EP-4132944-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION Cocrystal Pharma, Inc. (US) 2023-02-15 EP disclosed
WO-2023014758-A1 INHIBITORS FOR CORONAVIRUSES COCRYSTAL PHARMA, INC. (US) 2023-02-09 WO disclosed
WO-2023014758-A1 INHIBITORS FOR CORONAVIRUSES COCRYSTAL PHARMA, INC. (US) 2023-02-09 WO disclosed
CN-115698035-A Inhibitors of norovirus and coronavirus replication 共晶制药公司 2023-02-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240398757-A1 INHIBITORS FOR CORONAVIRUSES ACE, ACE2, SARS1 ACP3 3145/4885AOC3 1834/4885KIF11 2863/4885
US-20230159453-A1 INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION VIM, ACE, ACE2 ACP3 3927/4885AOC3 3010/4885KIF11 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.